• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Rises Sharply; BIOLASE Shares Plunge

    9/14/23 12:19:53 PM ET
    $BIOL
    $CMND
    $FWBI
    $IBEX
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIOL alert in real time by email

    U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday.

    The Dow traded up 0.61% to 34,784.94 while the NASDAQ rose 0.71% to 13,911.78. The S&P 500, also rose, gaining, 0.64% to 4,495.82.

    Check This Out: Top 5 Tech And Telecom Stocks You May Want To Dump In Q3

     

    Leading and Lagging Sectors

    Energy shares jumped by 1.2% on Thursday.

    In trading on Thursday, health care shares rose by just 0.1%.

     

    Top Headline

    U.S. initial jobless claims rose by 3,000 to 220,000 in the week ending Sept. 9, versus market estimates of 225,000.

     

    Equities Trading UP

    First Wave BioPharma, Inc. (NASDAQ:FWBI) shares shot up 59% to $0.6899 after the company announced license agreement for capeserod from Sanofi.

    Shares of PFSweb, Inc. (NASDAQ:PFSW) got a boost, shooting 48% to $7.43 after GXO Logistics announced it will acquire the company.

    MYT Netherlands Parent B.V. (NASDAQ:MYTE) shares were also up, gaining 16% to $4.36 after the company reported fourth-quarter financial results.

     

    Equities Trading DOWN

    IBEX Limited (NASDAQ:IBEX) shares dropped 21% to $14.40 after the company reported worse-than-expected fourth-quarter financial results and issued FY24 revenue guidance below estimates.

    Shares of Clearmind Medicine Inc. (NASDAQ:CMND) were down 56% to $0.1772. Clearmind Medicine announced pricing of $2.25 million public offering of 7.5 million shares at $0.30/share.

    BIOLASE, Inc. (NASDAQ:BIOL) was down, falling 40% to $1.94 after the company announced pricing of a $4.5 million underwritten public offering of Series J Convertible Redeemable Preferred Stock and warrants.

    Also Check This Out: Check Out 3 Industrials Stocks With Over 3% Dividend Yields From Wall Street's Most Accurate Analysts

     

    Commodities

    In commodity news, oil traded up 1.7% to $90.04 while gold traded down 0.2% at $1,928.20.

    Silver traded down 1.7% to $22.785 on Thursday while copper rose 0.4% to $3.8075.

     

    Euro zone

    European shares were higher today. The eurozone’s STOXX 600 rose 1.22% London’s FTSE 100 gained 1.67% while Spain’s IBEX 35 Index rose 1.09% The German DAX rose 0.67% French CAC 40 climbed 0.97%, while Italy’s FTSE MIB Index climbed 1.08%.

    The ECB raised interest rates for the 10th straight time on September 14.

     

    Asia Pacific Markets

    Asian markets closed mostly higher on Thursday, with Japan’s Nikkei 225 gaining 1.41%, Hong Kong’s Hang Seng Index rising 0.21% and China’s Shanghai Composite Index gaining 0.11%. India’s S&P BSE Sensex, meanwhile, rose 0.1%.

    India's wholesale prices fell by 0.52% year-over-year in August following a 1.36% decline in the earlier month. Industrial production in Japan fell by 1.8% month-over-month in July versus a final 2.4% increase in the prior month. Japan's core machinery orders declined 1.1% month-over-month in July following a 2.7% growth in June.

     

    Economics

    Producer prices in the U.S. rose by 0.7% in August 2023, higher than market expectations for a 0.4% increase.

    Retail sales in the U.S. rose 0.6% month-over-month in August following a revised 0.5% increase in July.

    U.S. initial jobless claims rose by 3,000 to 220,000 in the week ending Sept. 9, versus market estimates of 225,000.

    Total business inventories in the U.S. came in flat month-over-month in July versus a revised 0.1% decline in the previous month.

    U.S. natural gas supplies climbed 57 billion cubic feet last week, the EIA said.

    Now Read This: Over $6M Bet On ModivCare? Check Out These 3 Stocks Insiders Are Buying

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 108,386,680 cases with around 1,174,840 deaths. India confirmed a total of at least 44,997,910 cases and 531,930 deaths, while France reported over 40,138,560 COVID-19 cases with 167,640 deaths. In total, there were at least 695,248,690 cases of COVID-19 worldwide with more than 6,915,120 deaths.

    Get the next $BIOL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIOL
    $CMND
    $FWBI
    $IBEX

    CompanyDatePrice TargetRatingAnalyst
    IBEX Limited
    $IBEX
    5/12/2025$30.00Outperform → Neutral
    Robert W. Baird
    MYT Netherlands Parent B.V.
    $MYTE
    3/3/2025$13.00 → $14.00Hold → Buy
    TD Cowen
    IBEX Limited
    $IBEX
    11/10/2023$17.00Overweight → Neutral
    Piper Sandler
    IBEX Limited
    $IBEX
    9/14/2023$27.00 → $18.00Outperform → Sector Perform
    RBC Capital Mkts
    MYT Netherlands Parent B.V.
    $MYTE
    6/14/2023$19.00 → $4.00Buy → Hold
    Jefferies
    MYT Netherlands Parent B.V.
    $MYTE
    4/20/2023$7.00Buy → Hold
    Societe Generale
    MYT Netherlands Parent B.V.
    $MYTE
    4/19/2023$7.00Overweight → Neutral
    JP Morgan
    MYT Netherlands Parent B.V.
    $MYTE
    3/16/2023$13.00 → $7.00Outperform → Market Perform
    TD Cowen
    More analyst ratings

    $BIOL
    $CMND
    $FWBI
    $IBEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jones John William was granted 2,250 shares, increasing direct ownership by 17% to 15,244 units (SEC Form 4)

    4 - IBEX Ltd (0001720420) (Issuer)

    3/4/26 4:13:16 PM ET
    $IBEX
    EDP Services
    Technology

    Director Zhuang Mingzhe was granted 2,083 shares, increasing direct ownership by 42% to 7,083 units (SEC Form 4)

    4 - IBEX Ltd (0001720420) (Issuer)

    3/4/26 4:12:05 PM ET
    $IBEX
    EDP Services
    Technology

    Director Ballou-Aares Daniella was granted 2,083 shares, increasing direct ownership by 14% to 17,143 units (SEC Form 4)

    4 - IBEX Ltd (0001720420) (Issuer)

    3/4/26 4:10:51 PM ET
    $IBEX
    EDP Services
    Technology

    $BIOL
    $CMND
    $FWBI
    $IBEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

    Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market projected to exceed $200 billion by 2035 Vancouver, Canada, March 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT)

    3/10/26 8:59:00 AM ET
    $CMND
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

    The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial Vancouver, Canada, March 04, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that its independent Data and Safety Monitoring Board ("DSMB") has completed the second scheduled interim review of the Company's ongoing FDA-approved Phase I/IIa clinical trial for CMND-100, a propri

    3/4/26 7:30:00 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?

    HONG KONG, Feb. 19, 2026 /PRNewswire/ -- As the multi-billion-dollar obesity treatment market continues to search for new therapeutic approaches beyond GLP-1–based treatments, Clearmind Medicine (NASDAQ:CMND), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, recently reported additional progress related to its proprietary, non-hallucinogenic neuroplastogen, MEAI. In a world where obesity affects over a billion people globally, the search for truly transformative weight loss solutions has never been more urgent. Current blockbuster drugs like semaglutide and tirzepatide have rev

    2/19/26 1:05:00 PM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOL
    $CMND
    $FWBI
    $IBEX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    IBEX Ltd. downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded IBEX Ltd. from Outperform to Neutral and set a new price target of $30.00

    5/12/25 8:21:23 AM ET
    $IBEX
    EDP Services
    Technology

    Mytheresa upgraded by TD Cowen with a new price target

    TD Cowen upgraded Mytheresa from Hold to Buy and set a new price target of $14.00 from $13.00 previously

    3/3/25 7:34:14 AM ET
    $MYTE
    Catalog/Specialty Distribution
    Consumer Discretionary

    IBEX Ltd. downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded IBEX Ltd. from Overweight to Neutral and set a new price target of $17.00

    11/10/23 7:31:30 AM ET
    $IBEX
    EDP Services
    Technology

    $BIOL
    $CMND
    $FWBI
    $IBEX
    SEC Filings

    View All

    SEC Form 6-K filed by Clearmind Medicine Inc.

    6-K - Clearmind Medicine Inc. (0001892500) (Filer)

    3/10/26 9:29:59 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Clearmind Medicine Inc.

    6-K - Clearmind Medicine Inc. (0001892500) (Filer)

    3/4/26 9:01:06 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Clearmind Medicine Inc.

    EFFECT - Clearmind Medicine Inc. (0001892500) (Filer)

    2/27/26 12:15:18 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOL
    $CMND
    $FWBI
    $IBEX
    Financials

    Live finance-specific insights

    View All

    IBEX Reports Record Quarterly Revenue and EPS, Raises Fiscal Year Guidance

    Record second quarter Revenue, Adjusted EBITDA, EPS, and Adjusted EPSRevenue grew 17% versus prior year quarter, fourth consecutive quarter of double-digit growthEPS grew 45% year-over-year to $0.83 and adjusted EPS grew 46% to $0.87Raises Fiscal Year Revenue and Adjusted EBITDA Guidance WASHINGTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- IBEX Limited ("ibex"), a leading provider in global business process outsourcing and end-to-end customer engagement technology solutions, today announced financial results for its second fiscal quarter ended December 31, 2025.   Three Months Ended December 31, Six Months Ended December 31,($ millions, except per share amounts)  2025   2024  Change  2025   2024

    2/5/26 4:05:00 PM ET
    $IBEX
    EDP Services
    Technology

    IBEX Limited to Announce Second Quarter 2026 Financial Results on February 5, 2026

    WASHINGTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- IBEX Limited ("ibex") (NASDAQ:IBEX), a leading global provider of business process outsourcing (BPO) and AI-powered customer engagement technology solutions, today announced it will report second quarter 2026 financial results after the market close on Thursday, February 5, 2026. Management will host a conference call and webcast to discuss the Company's financial results, recent developments, and business outlook at 4:30 p.m. ET. What:IBEX Limited Announces Second Quarter 2026 Financial Results  When:Thursday, February 5, 2026  Time:4:30 p.m. ET  Live Call:Register Here for Dial-In and PIN  Webcast:Register Here for Webcast   About ibexibex de

    1/22/26 4:30:00 PM ET
    $IBEX
    EDP Services
    Technology

    IBEX Reports Record Start to Fiscal 2026, Raises Full Year Guidance

    Record first quarter Revenue, Adjusted EBITDA, EPS, Adjusted EPS, and Free Cash FlowRevenue grew 16.5% versus prior year quarterEPS grew 91% year-over-year to $0.82 and adjusted EPS grew 74% to $0.90Raises Fiscal Year Guidance WASHINGTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- IBEX Limited ("ibex") (NASDAQ:IBEX), a leading provider in global business process outsourcing and end-to-end customer engagement technology solutions, today announced financial results for its first fiscal quarter ended September 30, 2025.  Three months ended September 30,($ millions, except per share amounts) 2025   2024  ChangeRevenue$151.2  $129.7  16.5%Net income$12.0  $7.5  59.9%Net income margin 8.0%  5.8% 220 bps

    11/6/25 4:05:00 PM ET
    $IBEX
    EDP Services
    Technology

    $BIOL
    $CMND
    $FWBI
    $IBEX
    Leadership Updates

    Live Leadership Updates

    View All

    Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

    Vancouver, Canada, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received final approval from the Hadassah Medical Center, Jerusalem, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable Hadassah Medical Center, a leading clinical site in Israel, to join the Company's clinical trial, of which the fir

    11/13/25 8:54:39 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

    Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced the appointment of Mary-Elizabeth Gifford as Chief of Global Impact. In this role, Gifford will lead efforts to strengthen Clearmind's US partnerships, governmental and regulatory advocacy, and strategic alliances in Washington, D.C. and New York, bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines. Prior to joining Cl

    10/27/25 9:22:00 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ibex and Red Roof to Speak at the ICMI Contact Center Expo in Orlando

    ORLANDO, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- ibex (NASDAQ:IBEX), a leading global provider of business process outsourcing (BPO) and AI-powered customer engagement technology solutions, today announced it will participate in a joint session with Red Roof at the ICMI's Contact Center Expo, October 27-30, 2025, at the Loews Royal Pacific Resort. The expert panel discussion, titled "The CX Revolution in the Hospitality Industry: How Red Roof Transformed its Call Center into an Award-Winning, AI-Driven Experience," is scheduled on Wednesday, October 29th, from 4:00 - 5:00 p.m. Eastern time, and will include Shanna Wright, Vice President, Distribution Services, Red Roof; Katie Henshaw, Dir

    10/22/25 9:00:00 AM ET
    $IBEX
    EDP Services
    Technology

    $BIOL
    $CMND
    $FWBI
    $IBEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by IBEX Limited

    SC 13D/A - IBEX Ltd (0001720420) (Subject)

    12/6/24 7:28:26 PM ET
    $IBEX
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by IBEX Limited

    SC 13D/A - IBEX Ltd (0001720420) (Subject)

    11/22/24 4:17:06 PM ET
    $IBEX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Clearmind Medicine Inc.

    SC 13G/A - Clearmind Medicine Inc. (0001892500) (Subject)

    11/14/24 5:08:52 PM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care